International Business News - SGMO http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Among the stock activity stories for Tuesday, Nov. 11, from AP Financial News: NEW YORK (AP)--Taleo Corp. shares hit a new 52-week low Tuesday as analysts parsed the company's announcement that it will put off reporting third-quarter earnings to review its accounting practices. http://www.ibtimes.com/articles/20081111/movers-roundup-taleo-sangamo-biosciences.htm Tue, 11 Nov 2008 15:02:51 EST Shares of Sangamo BioSciences Inc. plunged to a six-year low Tuesday after the biotechnology company said a midstage study of its diabetic nerve pain candidate failed, raising questions about other studies of SB-509. http://www.ibtimes.com/articles/20081111/sangamo-stock-dives-after-nerve-pain-trial-fails.htm Tue, 11 Nov 2008 11:59:26 EST Sangamo BioSciences Inc. said Monday its developing drug aimed at treating pain associated with diabetes failed to meet its goal in a midstage study. The drug candidate, SB-509, showed no significant difference in treatment when compared with placebo in the 110-person study. It is still involved in two additional midstage studies. http://www.ibtimes.com/articles/20081111/sangamo-biosciences-drug-fails-midstage-study.htm Tue, 11 Nov 2008 07:18:45 EST Among the earnings stories for Wednesday, Oct. 29, from AP Financial News: NEWARK, N.J. (AP)--Insurance and investment company Prudential Financial says unfavorable market conditions drove it to report a third-quarter loss, reversing a year-ago profit. http://www.ibtimes.com/articles/20081029/earnings-roundup-prudential-metlife.htm Wed, 29 Oct 2008 18:47:06 EDT Sangamo BioSciences Inc. said Wednesday its loss widened in the third quarter as it spent more money to develop its nerve drug candidate SB-509. Sangamo reported a net loss of $6.3 million, or 15 cents per share, in the most recent quarter, compared with a net loss of $4.3 million, or 11 cents per share, a year earlier. Revenue rose 61 percent to $3.7 million from $2.3 million, but that was countered by more rapid growth in Sangamo's expenses as it tested SB-509 as a treatment for diabetic neuropathy and Lou Gehrig's disease. http://www.ibtimes.com/articles/20081029/sangamo-has-wider-3rd-qtr-loss-on-nerve-drug-costs.htm Wed, 29 Oct 2008 17:34:35 EDT Among the stock activity stories for Wednesday, Sept. 17, from AP Financial News: CARMEL, Ind. (AP)--Shares of Conseco Inc. shed half their value Wednesday, a day after the insurer announced that it held more than $100 million in securities of Lehman Brothers Holdings Inc. and two other troubled companies. http://www.ibtimes.com/articles/20080917/movers-roundup-conseco-sangamo-biosciences.htm Wed, 17 Sep 2008 14:20:56 EDT Shares of Sangamo BioSciences Inc. continued to slide with the broader market Wednesday as Wall Street grapples with a financial crisis that has stung investors. http://www.ibtimes.com/articles/20080917/sangamo-shares-fall-as-broader-market-slides.htm Wed, 17 Sep 2008 19:26:35 EDT Shares of Sangamo BioSciences Inc. rose Tuesday after the company released preliminary results from a mid stage trial of its drug candidate SB-509, which showed the drug helped improve nerve function in diabetes patients. http://www.ibtimes.com/articles/20080826/sangamo-rises-on-early-sb-509-trial-data.htm Tue, 26 Aug 2008 16:42:43 EDT Among the stock activity stories for Wednesday, July 9, from AP Financial News: Top stories: http://www.ibtimes.com/articles/20080709/movers-roundup-sangamo-gen-probe.htm Wed, 09 Jul 2008 18:18:06 EDT Among the stock activity stories for Wednesday, July 9, from AP Financial News: NEW YORK (AP)--Shares of Cleveland-Cliffs Inc. soared on Wednesday after the iron and coal miner raised its outlook due to higher steel prices and recent iron ore price settlements. http://www.ibtimes.com/articles/20080709/movers-roundup-cleveland-cliffs-sangamo-biosci.htm Wed, 09 Jul 2008 14:20:02 EDT Shares of Sangamo BioSciences Inc. jumped Wednesday after the developer of genetic-based therapies said it signed a licensing deal with pharmaceuticals giant Roche. http://www.ibtimes.com/articles/20080709/sangamo-biosciences-shares-gain-on-roche-deal.htm Wed, 09 Jul 2008 17:46:33 EDT Sangamo BioSciences Inc., which develops genetic-based therapies, said Monday data shows the company's technology can make certain cells in the immune system resistant to the HIV virus. http://www.ibtimes.com/articles/20080630/sangamo-technology-shows-promise-in-treating-hiv.htm Mon, 30 Jun 2008 09:23:33 EDT Dow AgroSciences' move to license genetic-based therapies from Sangamo Biosciences Inc. could mean a large infusion of cash with little loss of product rights for the biotechnology company, according to several analysts. http://www.ibtimes.com/articles/20080619/analysts-sangamos-dow-deal-could-be-key-driver.htm Thu, 19 Jun 2008 15:35:55 EDT Sangamo BioSciences Inc., which develops genetic-based therapies, said Thursday Dow AgroSciences exercised an option to license technology from Sangamo that turns genes on or off. http://www.ibtimes.com/articles/20080619/sangamo-licenses-gene-technology-for-crops-to-dow.htm Thu, 19 Jun 2008 08:44:12 EDT Among the stock activity stories for Friday, June 6, from AP Financial News: NEW YORK (AP)--Shares of Borders Group Inc. declined Friday along with the broader market, despite analyst optimism over the sale of some of the bookseller's international businesses. http://www.ibtimes.com/articles/20080606/movers-roundup-borders-sangamo-biosciences.htm Fri, 06 Jun 2008 14:53:44 EDT Shares of Sangamo BioSciences Inc. plunged Friday after the company said it will double the size of a midstage study and increase dosing for its nerve-disorder drug candidate, raising speculation that the drug is not meeting its intended treatment goal. http://www.ibtimes.com/articles/20080606/sangamo-shares-drop-on-plans-to-expand-study.htm Fri, 06 Jun 2008 16:53:52 EDT Shares of Sangamo Biosciences Inc. sank Thursday after an analyst said two trials of a key drug candidate are going to fail. Brean Murray Carret & Co analyst Jonathan Aschoff began coverage of the stock with a "Sell" rating and a target price of $5 per share, suggesting shares will fall almost 60 percent over the next year. He thinks two trials of SB-509 as a treatment for diabetic neuropathy will fail, and as a result, investors will expect less from the company's zinc finger protein technology. http://www.ibtimes.com/articles/20080529/sangamo-skids-as-analyst-doubts-zpf-success.htm Thu, 29 May 2008 17:39:45 EDT The president, chief executive and director of Sangamo Biosciences Inc. sold 25,000 shares of common stock under a prearranged trading plan, according to a Securities and Exchange Commission filing. http://www.ibtimes.com/articles/20080520/sangamo-biosciences-president-ceo-sells-shares.htm Tue, 20 May 2008 14:03:04 EDT